Whilst there are no head-to-head prospective study comparisons between fixed rate intravenous insulin infusion (FRIII) and VRIII in DKA, VRIII achieved early hyperglycemia correction and DKA resolution without increased hypoglycemia risk in an observational study of 97 patients with DKA [24]. This evidence concerns the gene INS and Hypoglycemia.